Alopecia Areata: Impact on Patients’ Quality of Life and Disease Perception: A Survey-Based Study
DOI:
https://doi.org/10.2340/actadv.v105.43318Keywords:
Alopecia areata, measurement tools, HRQoL, Dermatology, Hair, Impact on daily lifeAbstract
Alopecia areata significantly impacts patients’ emotional and psychosocial well-being. This survey investigated patients’ perspectives on disease severity and its impact on quality of life. The study evaluated whether disease assessment tools (Severity of Alopecia Tool, Dermatology Life Quality Index, and Patient Unique Stigmatization Holistic tool in dermatology) reflect patients’ perceptions of their condition. The study was conducted as an anonymous social media survey in Norway and Denmark. The questionnaire was divided into 3 main sections: (i) demographics and disease characteristics; (ii) disease severity and QoL measures; and (iii) patient perception and psychosocial impact. A total of 360 individuals participated in the survey reporting alopecia areata as mild (15%), moderate (29%), or severe (58%). Some 61% reported alopecia areata to interfere with their daily or weekly activities. All disease assessment tools demonstrated an age-dependent pattern, where scores were highest in the youngest (< 30 years) responder group. The relationship between Dermatology Life Quality Index and Severity of Alopecia Tool scores was found to be weak (R-squared = 0.08). Similarly, the correlation between Dermatology Life Quality Index and self-reported disease severity was also weak (R-squared = 0.136). This study demonstrates that there is a clear need for the development of more comprehensive, validated, and patient-centred assessment tools that can accurately reflect the physical, emotional, psychological, and social challenges faced by individuals with alopecia areata.
Downloads
References
Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata: current understanding and management. J Dtsch Dermatol Ges 2022; 20: 59–90. DOI: https://doi.org/10.1111/ddg.14689
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515–1525. DOI: https://doi.org/10.1056/NEJMra1103442
Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes 2020; 4: 76. DOI: https://doi.org/10.1186/s41687-020-00240-7
Rencz F, Gulacsi L, Pentek M, Wikonkal N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 561–571. DOI: https://doi.org/10.1111/bjd.14497
King BA, Senna MM, Ohyama M, Tosti A, Sinclair RD, Ball S, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb) 2022; 12: 825–834. DOI: https://doi.org/10.1007/s13555-022-00711-3
Rees H, Wall D, Bokhari L, Asfour L, Sinclair R. Reliability and validity of a measure to assess the health-related quality of life of women with alopecia areata. Clin Exp Dermatol 2023; 48: 681–684. DOI: https://doi.org/10.1093/ced/llad066
Frolunde AS, Gren ST, Frostrup AG, Poulsen PB, Vastrup AS, Vestergaard C. Outreach through Facebook: do patients with atopic dermatitis provide clinically relevant information when recruited for surveys on social media? JMIR Dermatol 2023; 6: e45226. DOI: https://doi.org/10.2196/45226
Danish legislation, Komiteloven Chapter 4, paragraph 14 [accessed May 15, 2025]. Available from: https://danskelove.dk/komit%C3%A9loven
Norwegian Ethical Committee guidelines [accessed May 15, 2025]. Available from: https://rekportalen.no/#hjem/s%C3%B8ke_REK
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines – part ii. National alopecia areata foundation. J Am Acad Dermatol 2004; 51: 440–447. DOI: https://doi.org/10.1016/j.jaad.2003.09.032
Lee JY, Lee JW, Lee WS. Comparison of self-estimated and clinician-measured SALT score in patients with alopecia areata: patients with alopecia areata perceive themselves as more severe than dermatologists. Indian J Dermatol Venereol Leprol 2024; 90: 235–237. DOI: https://doi.org/10.25259/IJDVL_439_2022
Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997–1035. DOI: https://doi.org/10.1111/j.1365-2133.2008.08832.x
Nicolescu AC, Ionescu MA, Constantin MM, Ancuta I, Ionescu S, Niculet E, et al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness. Life (Basel) 2022; 12: 2050. DOI: https://doi.org/10.3390/life12122050
Ezzedine K, Shourick J, Bergqvist C, Misery L, Chuberre B, Kerob D, et al. Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D): development and validation of a dermatology-specific stigmatization assessment tool. J Eur Acad Dermatol Venereol 2023; 37: 443–450. DOI: https://doi.org/10.1111/jdv.18641
Simonsen S, Stausholm KR, Pallesen K, Sedeh FB, Skov L. Danish guidelines for treatment of alopecia areata. Dansk Dermatologisk Selskab. Version July 2023.
Harries M, Ascott A, Asfour L, Farrant P, Hale G, Holmes S, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol 2025; 192: 190–205. DOI: https://doi.org/10.1093/bjd/ljae385
Hanson KA, Marwaha S, Kurosky SK, Harries M, Anderson P, Piercy J et al. An evaluation of generic and disease-specific patient-reported outcome measures to assess the impact of percentage of scalp hair loss on health-related quality of life in a European population. JEADV Clin Pract 2025; 4: 451–457. DOI: https://doi.org/10.1002/jvc2.591
Chernyshov PV, Tomas-Aragones T, Finlay AY, Manolache L, Marron SE, Sampogna S, et al. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol 2021; 35: 1614–1621. DOI: https://doi.org/10.1111/jdv.17370
Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol 2023; 37: 1490–1520. DOI: https://doi.org/10.1111/jdv.18926
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Christian Vestergaard, Daniel de la Rosa Carrillo, Randeep Mandla, Anne Grete Frøstrup, Susanne T. Gren, Petri Vänni, Anna-Kaisa Asikainen, Kristian Kofoed, Cato Mørk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
